La disponibilidad de estos agonistas duales y triples podra impactar significativamente el tratamiento futuro de la EHMET, especialmente en personas con DM2 y obesidad
The future of pemvidutide (and by extension Altimmune) rests on future trials showing weight reductions that match Wegovy or replicating NASH improvement trends from the Phase 1b (no small feat)
Biomarkers including fasting insulin, insulin resistance (HOMA-IR), and inflammatory markers (CRP) help providers understand whether plateau reflects metabolic adaptation, insufficient medication dosage, or lifestyle drift
Its not fair on my kids and my family
Retrieved from Hearn, E
For example, tirzepatide, a dual GLP-1 and GIP agonist, is FDA-approved under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight and at least one weight-related condition